Adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1), play a pivotal role in the inflammatory and immunological responses. They are initially upregulated on the endothelium by tumor necrosis factor-a (TNF-a) or interleukin-1 (IL-1) and go on to mediate the steps of leukocyte migration from the vasculature into the inflamed tissue, these leukocytes then promote the inflammatory response.
Also, the interaction of ICAM-1 and VCAM-1 expressed on antigen presenting cells with their ligands, such as lymphocyte function associated antigen-1 (LFA-1) and very late activation antigen-4 (VLA-4), has been involved in activation of T cells. [2] [3] [4] [5] Recently, the antigen recognition step has been visualized and ICAM-1 identified as one important component of the immunological synapse. 6) Hence, it is hoped that interfering with these interactions will not only have an effect on leukocyte infiltration, but also modulate T cell response. Furthermore, it has been reported that anti-adhesion molecule antibodies can ameliorate the inflammatory reaction and immunological parameters in various animal models. 7) For these reasons the development of cell adhesion molecule inhibitors as novel therapeutics for inflammatory and autoimmune diseases has been widely anticipated, and a considerable literature on such compounds has appeared. [8] [9] [10] [11] We have reported that the piperidine sulfonamide and sulfamide derivatives of 10H-pyrazino [2,3-b] [1, 4] benzothiazine 1a and 1b have potent ICAM-1 upregulation inhibitory activity and suppresses neutrophil infiltration in an IL-1-induced paw inflammation model. 12) We report here the effect of replacing the piperidine sulfonamide moiety of 1a in order to investigate further the structure-activity relationships of this family. Of particular interest to us was the introduction of a carboxylic acid group, a bioisostere of the sulfonamide function.
Chemistry We first prepared the right moieties of the compounds 2. The piperidine carboxylates 4a-c are either commercially available or known in the literature. 13, 14) The other piperidine carboxylates 4d-i and 4l-v were prepared as shown in Charts 1-11. The syntheses of 4d and 4e are shown in Chart 1. Coupling the aldehyde 6 15) with the appropriate Horner-Emmons reagent gave the unsaturated ester 7. Hydrogenation of the resulting ester 7 using 10% palladium on carbon (Pd/C) followed by deprotection of the piperidine amine group with 4 N HCl/AcOEt provided saturated ester 4d. The unsaturated ester 4e was also obtained by removal of the Boc group of compound 7 using the same procedure.
The acetylenic ester 4f was prepared as shown in Chart 2. Reaction of 4-piperidine aldehyde 9 with the Corey-Fuchs reagent provided dibromo compound 10. This compound was treated with n-butyllithium (n-BuLi) to afford the acetylide, which was reacted with ethyl chloroformate. 16 ) Deprotection of 11 provided acetylene intermediate 4f.
Piperidine Carboxylic Acid Derivatives of 10H-Pyrazino[2,3-b][1,4]benzothiazine as Orally-Active Adhesion Molecule Inhibitors
The amino-, oxy-and thio-acetic acid piperidine derivatives 4g-i were prepared as shown in Chart 3. The appropriate amino-or hydroxy-piperidine 12 or 14 was alkylated with ethyl bromoacetate followed by deprotection to give compounds 4g or 4h respectively. Mercaptopiperidine 17 was synthesized using the method of Barrera as shown in Chart 3. 17) Benzyl piperidone 16 was converted to its dithiol, which on reduction with sodium borohydride gave 17. Condensation of 17 with ethyl bromoacetate followed by removal of the benzyl group using 1-chloroethyl chloroformate (ACECl) afforded compound 4i.
The a,a-dimethyl ester 4l was synthesized as shown in Chart 4. Methylation of carboxylate 8 with methyl iodide followed by deprotection using HCl in AcOEt gave 4l.
Compound 4m was prepared as shown in Chart 5. N-Alkylation of hydroxypiperidine derivative 20 with benzyl bromide followed by dehydration using p-toluenesulfonic acid (p-TsOH) in toluene gave 1,2,5,6-tetrahydropyridine derivative 21. This bromide 21 was treated with n-BuLi followed by condensation with diethyl carbonate to furnish ester 22. Hydrogenation of 22 using Pearlman's catalyst yielded the benzoate derivative of piperidine 4m.
The synthesis of the phenylacetic acid derivative of piperidine 4n was achieved as illustrated in Chart 6. Treatment of benzyl piperidone 16 with phenyl Grignard reagent 23 followed by deprotection furnished the benzaldehyde 24. The phenylacetate 26 was obtained by condensation of aldehyde 24 with methyl methylsulfinylmethyl sulfide (FAMSO) and hydrolysis using 10% HCl/MeOH. Treatment of 26 with pTsOH, followed by hydrogenation using Pd(OH) 2 /C afforded the piperidine phenylacetate 4n.
The (7-azaspiro [3.5] non-2-yl)carboxylate 4o was prepared as shown in Chart 7. The cycloaddition reaction between olefin 28 18) and dichloroketene, generated in situ from trichloroacetyl chloride and zinc/copper, followed by reduction with zinc afforded the 7-azaspiro [3.5] nonane core of 29. Treatment of this ketone 29 with tosylmethyl isocyanide (TosMIC) in the presence of potassium tert-butoxide afforded the cyanide 30. Deprotection of the piperidine amino group with trifluoroacetic acid (TFA) followed by reprotection furnished the benzyl amine 31. Hydrolysis of the cyano moiety provided the carboxylic acid. Treatment with thionyl chloride in MeOH, then debenzylation using Pd(OH) 2 /C gave amine 4o.
Compound 4p was synthesized as shown in Chart 8. Compound 33, prepared by treatment of ketone 29 with the appropriate Horner-Emmons reagent, was hydrogenated over Pd/C to give saturated ester 34. Deprotection of the piperidine amino group using HCl/AcOEt gave amine 4p.
The syntheses of bicyclic amines 4q-v are shown in Charts 9-11. Compounds 4q and 4r were prepared as shown in Chart 9. Hydrogenation of unsaturated ester 35 19) using palladium on carbon provided a anti-syn mixture of 36 in the ratio of 3 : 1. This ratio was determined by integration of the equatorial protons of C-2 and C-4 in the 1 H-NMR spectra of the 3-azabicyclo[3.3.1]nonanes at 2.90 ppm (anti) and 2.62 ppm (syn) respectively. To separate the isomers, the protective group on the nitrogen was exchanged using vinyl chloroformate. The anti-and syn-isomers were isolated from the mixture using column chromatography (seven times) with a yield of 29% (37) and 13% (38) respectively. Chlorination of 37 or 38 with 4 N hydrochloric acid in dioxane, followed by hydrolysis afforded the important intermediates 4q or 4r respectively.
The syntheses of bicyclic intermediates 4s and 4v are shown in Chart 10. N-Demethylation of 35 or the known compound 39 20) using ACE-Cl provided the corresponding secondary amine.
Compounds 4t and 4u were synthesized as shown in Chart 11. Unsaturated esters 42 and 43, prepared by treatment of the ketones 40 21) and 41 22) with the appropriate Horner-Emmons reagent, were hydrogenated over Pd/C to give saturated esters 44 and 45. Deprotection of the amino group of the bicyclic ring using ACE-Cl gave the corresponding amines 4t and 4u.
With the exceptions of 2j, 2k and 2l, piperidine carboxylic acid derivatives of 10H-pyrazino [2,3- 12) with the appropriate piperidine carboxylates 4a-i and 4m-v in DMF using K 2 CO 3 provided the esters 5a-i and 5m-v. Hydrolysis of these esters under alkaline conditions provided the desired compounds 2a-i and 2m-v.
The synthesis of 2j is shown in Chart 13. Protection of readily available ester 46 12) with methoxymethyl chloride (MOMCl) gave the compound 47, which was reduced with lithium aluminum hydride (LiAlH 4 ) and chlorinated to afford the intermediate 49. Cyanation of 49 followed by hydrolysis and esterification gave 51. Reduction of this ester and methanesulfonylation followed by condensation with 4d gave 53. Deprotection then hydrolysis of 53 using 5 N HCl followed by NaOH afforded target compound 2j. The synthesis of amide junction derivative 2k is shown in Chart 14. Hydrolysis of ester 47 and subsequent condensation with piperidine ester 4d via the acid anhydride gave piperidine amide 56. Hydrolysis of ester 56 under alkaline conditions followed by deprotection with 5 N HCl gave carboxylic acid 2k.
The synthesis of a,a-dimethyl carboxylic acid derivative 2l is shown in Chart 15. Condensation between 49 and piperidine ester 4l gave compound 58. Hydrolysis of this ester 58 under alkaline conditions followed by deprotection of the N-methoxymethyl group of 59 with 5 N HCl gave carboxylic acid 2l.
Results and Discussion
The synthetic compounds were first evaluated for their in vitro inhibitory activity on the expression of the adhesion molecule ICAM-1 by TNF-a-stimulated human umbilical vein endothelial cells (HUVEC). The effect of the compounds on neutrophil accumulation after oral administration was evaluated in a mouse IL-1-induced paw inflammation model. In this model, myeloperoxidase activity was measured as the index of neutrophil infiltration. Table 1 summarizes the results of our initial studies with carboxylic acid derivatives. We first evaluated piperidine 4-carboxylic acid 2a. The ICAM-1 inhibitory activity of this compound was only 3-fold less than that of sulfonamide 1a. However 2a showed only 61.5% inhibition of neutrophil accumulation in the IL-1-induced paw model even at 100 mg/kg p.o. Simple replacement of the methansulfon-amide moiety of 1a by a carboxylic acid was shown not to be suitable. We went on to look for suitable linkers between the piperidine ring and carboxylic acid. Methylene-elongation enhanced inhibitory activity both in vitro and in vivo by about 2-3-fold (2b-d). Double bond insertion was also acceptable, but resulted in a slight loss of inhibitory activity in the IL-1 paw model (2e). Triple bond insertion led to a loss in potency of ICAM-1 inhibitory activity (2f). Introduction of a heteroatom such as oxygen or nitrogen into this linker resulted in loss of potency (2g, h). Thio derivative 2i also had only weak ICAM-1 inhibitory activity and low potency in the IL-1 paw model. Insertion of a heteroatom into this linker is clearly unfavorable.
Next, we modified the benzyl position Y between the 10H-pyrazino [2,3- carboxylic acid. We wished to prepare symmetric compounds that have significant activity in the IL-1 paw model as do 1a and 1b, but the a,a-dimethylcarboxylic acid derivative 2l showed only 21.7% inhibition in this model at a dose of 10 mg/kg p.o. Hence we investigated ring insertion. Introduction of a phenyl ring, such as in benzoic acid 2m and phenylacetic acid 2n, gave compounds with the same in vitro potency as 2d, though only 2n showed significant activity in the IL-1 paw model at a dose of 10 mg/kg p.o. This in vivo activity of 2n is 3-fold stronger than that of 2d and is comparable to that of 1. We speculated that aliphatic carboxylic acids may be more effective in providing in vivo active compounds than aromatic acids, and so 7-azaspiro[3.5]nonane derivatives such as 2o and 2p were prepared. These compounds retained ICAM-1 inhibitory activity and inhibited significantly neutrophil migration in the IL-1 paw model at a dose of 10 mg/kg p.o. The insertion of a rigid ring between the piperidine and aliphatic carboxylic acid is preferable for in vivo activity, and provides a good carrier moiety. We next focused on rigid ring systems such as bridged bicyclic derivatives in place of the piperidine ring. 3-Azabicyclo-[3.3.1]nonane ring derivatives 2q and 2r showed moderate in vitro inhibitory activities. Surprisingly, both compounds showed significant potency in the IL-1 induced paw model equivalent to that of 1b and 2n.
We further evaluated the potency of some carboxylic acid derivatives of 3-azabicyclo[3.3.1]nonane-like skeletons as shown in Table 4 . a,b-Unsaturated carboxylic acid 2s had 3-fold weaker ICAM-1 inhibitory activity compared to 2q. The 7-oxo derivative of 3-azabicyclo[3.3.1]nonane 2t also had 3-fold weaker potency than 2q, and no inhibitory activity in IL-1 paw model at a dose of 10 mg/kg. The potency of other bicyclic derivatives was examined. 3-Azabicyclo[3.2.1]octane derivative 2u showed significant activity both with respect to ICAM-1 inhibition and in the IL-1-induced paw inflammation model. But the tropane ring compound 2v lost potency towards ICAM-1 inhibition.
In our previous report, 12) the preferable ClogP value of sulfonamide derivatives, 1a and 1b that were highly potent in the IL-1 paw inflammation model, were stated to be around 0.6 as calculated using a previous version of ClogP software. We have also calculated and compared the values for carboxylic acid derivatives. The values of ClogP for 2n-r and 2u were within the range 1.27-2.59, and especially those of 2p-r were 1.9. 23) To compare the values for the two compound classes, the ClogP of 1a and 1b were re-calculated using the current version, and the results were 1.99 and 1.85, i.e. almost the same as the values of 2p-r in the carboxylic acid series. These trends indicate that a value for the lipophilic parameter ClogPԼ1.9 is a common important factor for activity for both types of compound in our in vivo models.
Of these compounds, we selected 2q for further evaluation. The inhibitory activity of 2q on other adhesion molecules was measured and the IC 50 for inhibition of VCAM-1 found to be 2.5 mM, and for E-selectin found to be 4.5 mM.
Compared with 1b, 2q showed moderate in vitro ICAM-1 inhibitory activity but strong potency in the IL-1-induced paw model at a dose of 10 mg/kg. We examined the plasma concentration of each compound at the time when in vivo potency was evaluated. As shown in Table 5 , 2q showed about 28-fold higher plasma concentration than 1b. Thus the strong inhibitory activity of 2q likely results mainly from its much higher plasma concentrations.
Furthermore, the effects of 2q and 1b were evaluated in the carrageenan-induced pleurisy model in the rat. Intrapleural injection of carrageenan induces leukocyte infiltration into the pleural cavity. An antibody to ICAM-1 has been reported effective in reducing leukocyte infiltration in the pleural cavity in this model. 24) Compound 2q significantly in- hibited leukocyte infiltration from a dose of 1 mg/kg p.o. The potency of compound 1b was 3-fold less than that of 2q.
The effect of compound 2q in the type II collagen-induced arthritis model in the rat was examined (Fig. 1) . In an experiment examining therapeutic treatment, compound 2q at doses of 2.5 to 20 mg/kg suppressed dose-dependently further increase in paw swelling.
Pharmacokinetic studies of 2q were carried out in the fed male rat (3 mg/kg p.o., 3 mg/kg i.v., nϭ2). This compound has a C max of 13.6 mM, a mean residence time (MRT) of 5.14 h, and an oral bioavailability of 98.5%. Due to its better pharmacokinetics in the rat, 2q also showed significant potency in the carrageenan pleurisy model in the rat, greater than might be predicted from its moderate in vitro ICAM-1 inhibition compared to that of 1b.
Conclusion
We have studied derivatives of compound 1 in which a carboxylic acid-containing group has been used as a bioisostere of the sulfonamide on the piperidine ring. Simple replacement of the sulfonamide gave a derivative with only moderate potency in the IL-1-induced paw inflammation model even at a dose of 100 mg/kg. By modifying the piperidine moiety, we found that rigid ring insertion, an aliphatic carboxylic acid and ClogPԼ1.9 are important for high in vivo activities. In particular, 2q significantly inhibited neutrophil migration in the mouse model at a dose of 10 mg/kg p.o. due to its good pharmacokinetic properties. In carrageenan-induced pleurisy model, 2q also exhibited preferable potency in leukocyte infiltration. And furthermore, 2q showed significant therapeutic effect in type II collagen-induced arthritis in rats. 2q (ER-49890) was selected as a candidate for further evaluation of its pharmacological properties. This compound is expected to be a promising drug candidate for the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis.
Experimental
Melting points were measured using a Yanako melting-point apparatus and are uncorrected. Proton nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a Varian Unity 400 (400 MHz) spectrometer, and chemical shifts are expressed in ppm downfield from tetramethylsilane (TMS) as an internal reference. The following abbreviations are used: sϭsinglet, dϭdou-blet, tϭtriplet, qϭquartet, quintϭquintet, sextϭsextet, septϭseptet, mϭ multiplet, brϭbroad. Mass spectra (MS) were obtained on a SSQ 7000 mass spectrometer. High resolution mass spectra (HR-MS) were obtained on a QTof ultima global mass spectrometer. Elemental analysis was performed with a Elemental Analyzer vario EL III. Materials were used as bought without any special purification. Silica gel (Kieselgel 60, Merck) was used for column chromatography, and silica gel (Kieselgel 60 F 254 , layer thickness 0.25 mm, Merck) for analytical thin layer chromatography (TLC). All organic extracts were dried over anhydrous MgSO 4 , and solvents were removed with a rotary evaporator under reduced pressure.
Ethyl (E)-4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-2-methyl-2-butenoate (7)
To a suspension of sodium hydride (NaH, 60% dispersion in mineral oil, 5.2 g, 130 mmol) in N,N-dimethylformamide (DMF, 200 ml) was added triethyl 2-phosphonopropionate (31 g, 130 mmol) at room temperature (rt), and the mixture was stirred at the same temperature for 30 min. To this solution was added a solution of 6 15) (21 g, 92 mmol) in DMF (100 ml) at 0°C, and the reaction mixture was stirred at rt for 12 h. The resulting mixture was poured into ice-water, and extracted with ethyl acetate (AcOEt). The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (10% AcOEt-hexane) to give 26 g (90%) of 7 as a colorless oil. Table 7 . Pharmacokinetic Property of 2q and 1b 12) in Rats MRT is mean residence time. A suspension of 7 (13.8 g, 44.3 mmol) and 10% palladium on carbon (Pd/C, 0.95 g) in ethanol (EtOH, 100 ml) was stirred under a hydrogen atmosphere at rt for 2 d. The catalyst was removed by filtration and the filtrate was concentrated to give 12.1 g (87%) of 8 as a colorless oil. 1 
Ethyl 4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]propynate (11)
To a solution of carbon tetrabromide (13 g, 38 mmol) and triphenylphosphine (20 g, 76 mmol) in dichloromethane (CH 2 Cl 2 , 200 ml) was added dropwise a solution of 9 (4.0 g, 19 mmol) in CH 2 Cl 2 (20 ml) at 0°C, and the mixture was stirred at 0°C for 1 h. This solution was diluted with diethyl ether (Et 2 O, 200 ml), and the precipitate was filtered off. The filtrate was concentrated in vacuo. The residue was chromatographed on silica gel (6% AcOEt-hexane) to give 5.7 g (81%) of 10 as a colorless oil. To a solution of 10 (2.7 g, 7.3 mmol) in tetrahydrofuran (THF, 50 ml) was added n-butyllithium (nBuLi, 1.0 M solution in hexane, 15 ml, 15 mmol) at Ϫ78°C under a nitrogen atmosphere, and the mixture was stirred at Ϫ78°C for 1 h and at 0°C for 1 h. Ethyl chloroformate (2.5 ml, 26 mmol) was added at Ϫ78°C, and the reaction mixture was allowed to warm to rt. The resulting mixture was poured into water, and extracted with AcOEt. The extract was washed with brine, dried and evaporated. The residue was chromatographed on silica gel (10% AcOEt-hexane) to give 2.1 g (quant.) of 11 as a colorless oil. 
Ethyl [1-(Benzyl)piperidin-4-yl]aminoacetate (13)
To a suspension of 1-benzyl-4-aminopiperidine 12 (10 g, 53 mmol) and potassium carbonate (K 2 CO 3 , 11 g, 80 mmol) in DMF (50 ml) was added ethyl bromoacetate (5.8 ml, 52 mmol) at 0°C over 20 min, and the mixture was stirred at rt for 12 h. The resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on NH silica gel (Fuji Silysia, DW2035, 10% AcOEt-hexane) to give 12 g (82%) of 13 as a colorless oil. 
Ethyl [1-(tert-Butoxycarbonyl)piperidin-4-yl]oxyacetate (15)
To a solution of 1-tert-butoxycarbonyl-4-piperidinol 14 (8.0 g, 40 mmol) in DMF (100 ml) was added NaH (60% dispersion in mineral oil, 1.8 g, 45 mmol) at rt, and the mixture was stirred at rt for 2 h. Ethyl bromoacetate (5.3 ml, 48 mmol) was added dropwise at 0°C, and the reaction mixture was stirred at rt for 2 h. The resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (10% AcOEt-hexane) to give 4.1 g (36%) of 15 as a colorless oil. 
Ethyl [1-(Benzyl)piperidin-4-yl]thioacetate (18)
Hydrogen sulfide was bubbled into a solution of 1-benzyl-4-piperidone 16 (18.9 g, 100 mmol) in isopropyl alcohol (iPrOH, 100 ml) at rt for 4 h. After stirring of the mixture at rt for 67 h, the solution was concentrated. To a solution of this residue in iPrOH (100 ml) was added sodium borohydride (5.7 g, 150 mmol) in portions at rt. After stirring of the mixture at 55°C for 2 h, 1 N HCl was added and the solution was stirred at 55°C for 1 h. The resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated to give 21.0 g (quant.) of 17 as a pale yellow oil. To a suspension of 17 (21.0 g, 100 mmol) and K 2 CO 3 (13.8 g, 100 mmol) in acetonitrile (200 ml) was added a solution of ethyl bromoacetate (10 ml, 90 mmol) in acetonitrile (50 ml) at rt over 1 h. After stirring of the mixture at rt for 16 h, the resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with 1 N NaOH, brine, dried, and evaporated. The residue was chromatographed on silica gel (20% AcOEt-hexane) to give 20.3 g (69%) of 18 as a colorless oil. 
Ethyl 4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-2,2-dimethylbutanoate (19)
To a solution of diisopropylamine (5.4 ml, 39 mmol) in THF (50 ml) was added n-BuLi (2.5 M solution in hexane, 15 ml, 38 mmol) at Ϫ10°C under a nitrogen atmosphere, and the mixture was stirred at 0°C for 30 min.
After cooling of the mixture to Ϫ78°C, a solution of 8 (3.0 g, 9.6 mmol) in THF (10 ml) was added at Ϫ78°C, and the mixture was stirred at 0°C for 30 min. After recooling of the mixture to Ϫ78°C, methyl iodide (3.0 ml, 48 mmol) was added, and the mixture was allowed to warm to rt. The resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (10% AcOEt-hexane) to give 1. Bromophenyl)-1-benzyl-1,2,5,6 -tetrahydropyridine (21) To a suspension of 20 (20 g, 78 mmol) and K 2 CO 3 (16.2 g, 117 mmol) in DMF (100 ml) was added benzyl bromide (11.1 ml, 93.3 mmol) dropwise at 0°C over 20 min, and the mixture was stirred at rt for 12 h. The reaction mixture was poured into ice-water and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (50% AcOEt-hexane) to give 27 g (quant.) of the benzyl amine as a colorless solid. A mixture of this amine (27 g, 78 mmol) and p-toluenesulfonic acid monohydrate (p-TsOH · H 2 O, 30.0 g, 158 mmol) in toluene (100 ml) was refluxed under Dean-Stark conditions for 1 h. The resulting mixture was cooled to 0°C, then was poured into a mixture of K 2 CO 3 -water-AcOEt, and the precipitated solid was filtered off. The filtered solution was extracted with AcOEt. The extract was washed with brine, dried, and evaporated to give 8. 
4-(4-

Ethyl 4-(1-Benzyl-1,2,5,6-tetrahydropyridin-4-yl)benzoate (22)
To a solution of 21 (8.7 g, 27 mmol) in THF (200 ml) was added n-BuLi (2.6 M solution in hexane, 13.5 ml, 35.1 mmol) at Ϫ78°C under a nitrogen atmosphere, and the mixture was stirred at Ϫ78°C for 15 min. To this solution was added diethyl carbonate (34.0 ml, 281 mmol) at Ϫ78°C, and the mixture was stirred from Ϫ78°C to rt over 3 h. The resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (10% AcOEt-hexane) to give 2.4 g (28%) of 22 as a yellow oil. 
4-(1-Benzyl-4-hydroxypiperidin-4-yl)benzaldehyde (24)
To a suspension of magnesium (0.74 g, 32 mmol) in THF (20 ml) was added a solution of 4-bromobenzaldehyde diethyl acetal (5.0 ml, 25 mmol) in THF (10 ml) at 40°C under a nitrogen atmosphere, and the mixture was stirred at rt for 30 min. After cooling of the mixture to 0°C, a solution of 1-benzyl-4-piperidone 16 (5.6 g, 31 mmol) in THF (10 ml) was added at below 10°C, and the mixture was stirred at rt for 1 h. To this reaction mixture was added first an aqueous solution of ammonium chloride (NH 4 Cl, 50 ml) and then 5 N HCl until the pH 1 reached. The mixture was stirred at rt for 1 h, an aqueous solution of sodium hydrogen carbonate (NaHCO 3 ) was added, and then the mixture was extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (70% AcOEt-hexane) to give 4.0 g (54%) of 24 as a yellow oil. 
Methyl 4-(1-Benzyl-4-hydroxypiperidin-4-yl)phenylacetate (26)
To a solution of 24 (11.2 g, 38 mmol) in THF (100 ml) was added methyl methylsulfinylmethyl sulfide (FAMSO, 39.6 g, 319 mmol) and 40% benzyltrimethylammonium hydroxide in methanol (40 ml) at rt, and the reaction mixture was refluxed for 4 h. After cooling of the mixture to rt, the resulting mixture was concentrated in vacuo. The residue was poured into water and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (20% MeOH-CH 2 Cl 2 ) to give 26 g of crude 25 as a yellow oil. A solution of 25 (26 g, 38 mmol) in 10% HCl-MeOH (400 ml) was refluxed for 6 h. After cooling and evaporation of the solvent, the residue was poured into an aqueous solution of K 2 CO 3 and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (70% AcOEt-hexane) to give 5.6 g (43%) of 26 as a yellow oil. Benzyl-1,2,5,6 -tetrahydropyridin-4-yl)phenylacetate (27) A mixture of 26 (5.8 g, 17 mmol) and p-TsOH · H 2 O (6.5 g, 34 mmol) in toluene (100 ml) was refluxed under Dean-Stark conditions for 30 min. After cooling to 0°C, the mixture was poured into an aqueous solution of NaHCO 3 at 0°C and the precipitate was filtered. The filtrate was extracted with AcOEt. The extract was washed with brine, dried, and evaporated. A solution of this residue and the filtrated precipitate in 10% HCl-MeOH (100 ml) was refluxed for 2 h. The reaction mixture was concentrated in vacuo, and poured into an aqueous solution of NaHCO 3 at 0°C, then the mixture was extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (30% AcOEt-hexane) to give 3.4 g (62%) of 27 as a pale yellow solid. mp 58-59°C. 18) (11.4 g, 57.9 mmol) in Et 2 O (180 ml) was added a solution of trichloroacetyl chloride (35.0 ml, 314 mmol) in 1,2-dimethoxyethane (DME, 100 ml) dropwise at rt under a nitrogen atmosphere. After stirring of the mixture at rt for 12 h, the reaction mixture was poured into an aqueous solution of NaHCO 3 at 0°C, and filtrated. The filtrate was extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was passed though silica gel (20% AcOEt-hexane) to afford 29 g of the crude dichloroketone as a pale brown oil. To a solution of this oil in saturated NH 4 Cl-MeOH (400 ml) was added zinc (40.0 g, 612 mmol) portion wise at rt. The reaction mixture was stirred at rt for 8 h, and then filtered. The filtrate was concentrated in vacuo. The residue was chromatographed on silica gel (20% AcOEt-hexane) to give 14 g (quant.) of 29 as a colorless solid. mp 55-56°C. 
Methyl 4-(1-
[7-(tert-Butoxycarbonyl)-7-azaspiro[3.5]non-2-yl]carbonitrile (30)
To a suspension of 29 (6.0 g, 25 mmol) and p-tosylmethyl isocyanide (TosMIC, 5.4 g, 28 mmol) in DME (50 ml) was added a solution of potassium tert-butoxide (5.6 g, 50 mmol) in tert-butanol (25 ml)-DME (25 ml) at 10°C-rt over 1 h under a nitrogen atmosphere. After stirring of the mixture at rt for 12 h, the reaction mixture was poured into ice-water, then extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (20% AcOEt-hexane) to give 2.1 g (33%) of 30 as a colorless solid. mp 65-66.5°C. 2 Cl 2 (40 ml) was added trifluoroacetic acid (40 ml, 520 mmol) at 0°C, and the reaction mixture was stirred at rt for 2.5 h. The resulting mixture was poured into an aqueous solution of NaHCO 3 , and extracted with AcOEt. The extract was washed with brine, dried, and evaporated to give 3.7 g (quant.) of crude secondary amine as a pale brown oil. To a solution of this amine and triethylamine (8.2 ml, 59 mmol) in CH 2 Cl 2 (50 ml) was added benzyl bromide (3.1 ml, 26 mmol) at 0°C, and the mixture was stirred at rt for 3 h. The resulting mixture was poured into water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on NH silica gel (10% AcOEt-hexane) to give 1.9 g (31%) of 31 as a colorless solid. mp 38-39°C. 
Methyl (7-Benzyl-7-azaspiro[3.5]non-2-yl)carboxylate (32)
A mixture of 31 (3.8 g, 16 mmol) and KOH (7.0 g, 130 mmol) in ethylene glycol (30 ml) was stirred at 180°C for 10 h. After cooling of the mixture to rt, sodium dihydrogenphosphate (NaH 2 PO 4 ) was added to a suspension of the residue in MeOH (500 ml), and the salt was filtrated off. The filtrate was concentrated in vacuo. To a solution of this carboxylic acid in MeOH (500 ml) was added thionyl chloride (10 ml, 140 mmol) at 0°C. The resulting mixture was stirred at rt for 3 d, then concentrated in vacuo. The residue was poured into an aqueous solution of NaHCO 3 , and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on NH silica gel (10% AcOEt-hexane) to give 3.7 g (84%) of 32 as a pale brown solid. mp 41. 
Ethyl (anti)-(3-Vinyloxycarbonyl-3-azabicyclo[3.3.1]non-9-yl)acetate (37) and Ethyl (syn)-(3-Vinyloxycarbonyl-3-azabicyclo[3.3.1]non-9-yl)acetate (38)
To a solution of 36 (2.2 g, 9.8 mmol) in 1,2-dichloroethane (20 ml) was added vinyl chloroformate (4.2 ml, 49 mmol) at 0°C. After stirring of the mixture at 0°C for 30 min, the mixture was refluxed for 3 h. After cooling of the reaction mixture to rt, the volatiles were removed under reduced pressure. The residue was poured into an aqueous solution of NaHCO 3 and extracted with AcOEt. The extract was washed with brine, dried and evaporated. The residue was chromatographed on silica gel (10% AcOEt-toluene) seven times to give 0.80 g (29%) of 37 and 0.35 g (13%) of 38 as a colorless oil. 37; 
Ethyl (3-Methyl-7-oxo-3-azabicyclo[3.3.1]non-9-ylidene)acetate (42)
In the same manner as described for the preparation of 33, 42 was obtained from 40 21) and triethyl phosphonoacetate as a colorless oil (59%). 
Ethyl (3-Methyl-3-azabicyclo[3.2.1]oct-8-ylidene)acetate (43)
In the same manner as described for the preparation of 33, 43 was obtained from 41 22) and triethyl phosphonoacetate as a colorless oil (42% 3 g, 8.3 mmol) , and K 2 CO 3 (1.7 g, 12 mmol) in DMF (30 ml) was stirred at 60°C for 3 h. After cooling of the mixture to rt, the resulting mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (3% MeOH-CH 2 Cl 2 ) to give 1.0 g (67%) of 5a as a yellow solid. mp 126-127°C. 
Ethyl 3-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]propionate (5c)
In the same manner as described for the preparation of 5a, 5c was obtained from 3 and ethyl 3-(piperidin-4-yl)propionate 14) as a yellow solid (63% 
3-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]propionic Acid (2c)
To a solution of 5c (0.50 g, 1.3 mmol) in EtOH (10 ml)-THF (10 ml) was added 1 N NaOH (3.9 ml, 3.9 mmol) under a nitrogen atmosphere, and the mixture was stirred at 60°C for 1 h. After cooling of the mixture to rt, the reaction mixture was concentrated in vacuo. The residue was diluted with water, and washed with AcOEt. The water phase was concentrated to 1/2 volume. The residue was poured slowly into an aqueous solution of NaH 2 PO 4 . After stirring of the mixture at rt for 20 min, the precipitate was collected and dried to obtain 0.39 g (81%) of 2c as a yellow solid. mp 135-136°C.
1 H-NMR (DMSO-d 6 
4-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-2-methylbutanoic Acid (2d)
In the same manner as described for the preparation of 2c, 2d was obtained from 5d as a yellow solid (79%). mp 187-188°C. 
Ethyl (E)-4-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]-2-methylbutenoate (5e)
In the same manner as described for the preparation of 5d, 5e was obtained from 7 and 3 as a yellow solid (44%). mp 120-121°C. 
Ethyl 3-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]propynate (5f)
To a solution of 11 (0.80 g, 2.8 mmol) and anisole (5 ml) in CH 2 Cl 2 (5 ml) was added trifluoroacetic acid (5.0 ml, 65 mmol) at rt, and the mixture was stirred at rt for 30 min. The resulting mixture was poured into NaHCO 3 -ice-water, and extracted with AcOEt. The extract was dried, and evaporated to give crude 4f as a yellow oil. A mixture of this oil, 3 (0.54 g, 2.2 mmol) and K 2 CO 3 (0.91 g, 6.6 mmol) in DMF (20 ml) was stirred at 60°C for 3 h. After cooling to 0°C, the mixture was poured into ice-water, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The residue was chromatographed on silica gel (60% AcOEt-CH 2 Cl 2 ) to give 0.53 g (61%) of 5f as a yellow solid. mp 129-130°C. [1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl] propynoic Acid (2f) In the same manner as described for the prepara-tion of 2a, 2f was obtained from 5f as a yellow solid (94% (5g) (1) A suspension of 13 (2.5 g, 9 .0 mmol) and 20% Pd(OH) 2 /C (0.9 g) in EtOH (30 ml) was stirred at rt for 6 h under a hydrogen atmosphere (4 kg/cm 2 ). The catalyst was removed by filtration and the filtrate was concentrated to give 1.7 g (quant.) of 4g as a colorless oil. (2) In the same manner as described for the preparation of 5a, 5g was obtained from 4g and 3 as yellow oil (74%). (1) To a solution of 18 (3.0 g, 10 mmol) in 1,2-dichloroethane (19 ml) was added 1-chloroethyl chloroformate (2.8 ml, 26 mmol) dropwise at 0°C over 30 min under a nitrogen atmosphere. After stirring at 0°C for 15 min, the mixture was heated to 100°C for 1 h, then concentrated in vacuo. A solution of this residue in EtOH (300 ml) was refluxed for 2 h, then the solvent was removed under reduced pressure to give 2.4 g (quant.) of secondary amine 4i as a pale brown solid. (2) A suspension of this amine 4i (1.2 g, 5.0 mmol), 3 (1.0 g, 4.0 mmol) and K 2 CO 3 (2.2 g, 16 mmol) in DMF (20 ml) was stirred at 70°C for 3 h. After cooling to 0°C, the mixture was poured into ice-water and extracted with AcOEt. The extract was washed with brine, dried and evaporated. The residue was chromatographed on silica gel (70% AcOEt-CH 2 Cl 2 ) to give 0.86 g (51%) of 5i as a yellow solid. mp 87-88°C. (2) A suspension of this amine 4m (1.3 g, 5.6 mmol), 3 (1.1 g, 4.4 mmol) and K 2 CO 3 (1.8 g, 13 mmol) in DMF (20 ml) was stirred at 60°C for 3 h under a nitrogen atmosphere. After cooling to rt, the mixture was poured into ice-water and extracted with AcOEt. The extract was washed with brine, dried and evaporated. The residue was chromatographed on silica gel (50% AcOEt-CH 2 Cl 2 ) to give 1.3 g (65%) of 5m as a yellow solid. mp 165-166°C. 1 (2) In the same manner as described for the preparation of 5m, step 2, 5n was obtained from 4n and 3 as a yellow solid (84%). mp 142-143°C. 1 (2) In the same manner as described for the preparation of 5m, step 2, 5o was obtained from 4o and 3 as a yellow solid (80%). mp 183-184°C. (2) A suspension of this amine 4q (0.36 g, 1.8 mmol), 3 (0.28 g, 1.1 mmol) and K 2 CO 3 (0.70 g, 5.1 mmol) in DMF (10 ml) was stirred at 80°C for 3 h under a nitrogen atmosphere. After cooling to 0°C, the mixture was poured into ice-water and extracted with AcOEt. The extract was washed with brine, dried and evaporated. The residue was chromatographed on silica gel (15% AcOEt-toluene) to give 0.27 g (57%) of 5q as a yellow solid. mp 142-143°C. (2) In the same manner as described for the preparation of 5q, step 2, 5r
3-
was obtained from 4r and 3 as a yellow solid (65% .0 mmol) in 1,2-dichloroethane (8.4 ml) was added 1-chloroethyl chloroformate (2.9 ml, 27 mmol) dropwise at 0°C for 30 min under a nitrogen atmosphere. After stirring at 0°C for 15 min, the mixture was heated to 100°C for 1 h, then concentrated in vacuo. A solution of this residue in EtOH (100 ml) was refluxed for 2 h, then the solvent was removed under reduced pressure to give 2.2 g (quant.) of secondary amine 4s as a pale yellow oil. A suspension of this amine 4s (2.2 g, 9.0 mmol), 3 (1.5 g, 6.0 mmol) and K 2 CO 3 (3.3 g, 24 mmol) in DMF (20 ml) was stirred at 80°C for 3 h under a nitrogen atmosphere. After cooling to 0°C, the mixture was poured into ice-water and extracted with AcOEt. The extract was washed with brine, dried and evaporated. The residue was chromatographed on silica gel (15% AcOEt-toluene) to give 1.6 g (64%) of 5s as a yellow solid. mp 45-46°C. 1 12) (415 g, 1.60 mol) in DMF (2.5 l) was added NaH (60% dispersion in mineral oil, 66.0 g, 1.65 mol) portion wise at Ϫ10-0°C, and the mixture was stirred at 0°C for 1 h. To this solution was added chloromethyl methyl ether (110 g, 1.37 mol) at below 5°C, and the reaction mixture was stirred at rt for 2 h. The resulting mixture was poured into ice-water, and extracted with CH 2 Cl 2 . The extract was washed with water, dried, and evaporated. The precipitate was washed with diisopropyl ether to give 335 g (69%) of 47 as a yellow solid. mp 151-152°C. 3 mmol) in THF (20 ml) was added a solution of 47 (2.0 g, 6.6 mmol) in THF (30 ml) at 0°C. The resulting mixture was stirred at 0°C for 1 h, and water was added dropwise (0.2 ml), followed by 15% aqueous sodium hydroxide solution (0.2 ml), and finally water (0.6 ml). After stirring for 30 min, the reaction mixture was filtered and the filtrate was evaporated. The residue was chromatographed on silica gel (60% AcOEt-hexane) to give 1.6 g (86%) of 48 as a yellow solid. mp 92-93°C. ) and pyridine (7.4 ml, 92 mmol) in DMF (70 ml) was added dropwise methanesulfonyl chloride (7.0 ml, 90 mmol) at 0°C under a nitrogen atmosphere. The resulting mixture was stirred at rt for 1 h, then was poured into an aqueous solution of NaHCO 3 at 0°C, and extracted with AcOEt. The extract was washed with brine, dried, and evaporated. The precipitate was washed with ether to give 7.1 g (67%) of 49 as a yellow solid. mp 125-126°C. 
